Kidney Cancer

The Food and Drug Administration granted a fast track designation to ADI-270, an off-the-shelf CAR-T cell therapy for clear cell renal cell carcinoma.

I was diagnosed with kidney cancer and pancreatic neuroendocrine tumors two years ago, but I’ve learned a lifetime of lessons since.

Patients who received systemic therapy at the end of life did not have longer overall survival averages than those who did not receive therapy at end of life.

Learning that I had cancer — melanoma and renal cell carcinoma — made me feel like I lost something, but I keep looking ahead.

During my time with cancer, I've come across words associated with cancer that I don't like and some that I appreciate.

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

This is the poem I wrote to help myself cope with my new diagnosis. It served as a reminder that I was resilient.

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy.

Anxiety over scans makes sense, but isn’t there more anxiety about other cancer tests, too?

Across disease stages, Black patients with renal cell carcinoma experience worse survival outcomes than White patients, research has shown.

Patients with inoperable kidney cancer saw significant results in local control and cancer-specific survival with stereotactic ablative body radiotherapy.

Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®.

When life hands you cancer lemons, what flavored lemonade do you make?

Researchers have determined distinguishing characteristics of TFE3-rearranged renal cell carcinoma.

Artificial intelligence platform ChatGPT is capable of providing “widely understandable and accessible” answers about kidney cancer, but experts express caution.

Welireg outperformed Afinitor in time to disease progression and patient-reported quality of life in the treatment of metastatic clear cell renal cell carcinoma.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

Real-world data demonstrated that knowing a patient’s stage and subtype of renal cell carcinoma, a type of kidney cancer, may provide cancer teams with the information needed to determine potential prognosis and recurrence risk.

Subcutaneous Opdivo led to similar outcomes to intravenous administration of the drug and may be easier to access down the road, an expert said.

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.

After cancer, taking baby steps towards stuff you want to do is what matters.

Some with metastatic cancers receiving end-of-life-initiated immunotherapy may have a decreased risk of mortality when treated at a high-volume facility, research found.

Recently, I have been focusing on the concept of Mattering, and it has boosted my mental health.

We all know that stress is bad.